Novo Nordisk initiated with an Equal Weight at Morgan Stanley
Morgan Stanley initiated coverage of Novo Nordisk (NVO) with an Equal Weight rating and DKK 700 price target The firm says near-term U.S.
Bernstein raises Novo Nordisk stock target to DKK620
Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.
Morgan Stanley sets Novo Nordisk stock at Equalweight
Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
clinicaltrialsarena on MSN10h
OCT West Coast 2025: China surpasses US for annual number of clinical trials
GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE:NVO) between November 2, 2022 ...